간암 마커로서의 LCN2 유전자, 단백질 및 간암 진단키트
    8.
    发明公开
    간암 마커로서의 LCN2 유전자, 단백질 및 간암 진단키트 失效
    LIPOCALIN 2作为肿瘤相关标记的肝细胞癌和使用其的肝细胞癌诊断试剂盒

    公开(公告)号:KR1020090029338A

    公开(公告)日:2009-03-23

    申请号:KR1020070094494

    申请日:2007-09-18

    CPC classification number: G01N33/5308 G01N33/57438

    Abstract: A hepatocellular carcinoma diagnostic kit containing a lipocalin 2 gene or their fraction and antibody is provided to increase the accuracy of the liver cancer diagnosis by performing the analysis by using the overexpression phenomenon of LCN2 in tissue, cells or body fluid of hepatocellular carcinoma patients. A hepatocellular carcinoma diagnostic kit comprises an antibody which is specifically bonded with the LCN2 protein. The hepatocellular carcinoma diagnostic kit comprises SEQ ID NO:3 which is specifically bonded with LCN2 mRNA or the nucleotide of SEQ ID NO:4. The hepatocellular carcinoma is diagnosed with the increment of the LCN2 protein amount. The mRNA quantity detection method uses RT-PCR(Reverse transcription polymerase chain reaction), competitive RT-PCR, realtime RT-PCR, RNase protection assay, Nothern blotting or DNA chip.

    Abstract translation: 提供含有脂质运载蛋白2基因或其部分和抗体的肝细胞癌诊断试剂盒,通过使用LCN2在肝细胞癌患者的组织,细胞或体液中的过表达现象进行分析,提高肝癌诊断的准确性。 肝细胞癌诊断试剂盒包括与LCN2蛋白特异性结合的抗体。 肝细胞癌诊断试剂盒包含与LCN2 mRNA特异性结合的SEQ ID NO:3或SEQ ID NO:4的核苷酸。 诊断为肝细胞癌的LCN2蛋白量增加。 mRNA量检测方法采用RT-PCR(逆转录聚合酶链反应),竞争性RT-PCR,实时RT-PCR,RNA酶保护试验,Nothern印迹法或DNA芯片。

    알파1산 당단백질과 아사이알로 알파1산 당단백질의 비율을 이용한 간질환 진단킷트
    10.
    发明公开
    알파1산 당단백질과 아사이알로 알파1산 당단백질의 비율을 이용한 간질환 진단킷트 有权
    用于测量比例血清脂质α的方法:1-酸的葡萄球蛋白浓度和用于诊断肝炎疾病的α-1酸甘氨酸浓度及其制剂

    公开(公告)号:KR1020080048200A

    公开(公告)日:2008-06-02

    申请号:KR1020060118248

    申请日:2006-11-28

    Abstract: A method for diagnosing hepatic diseases is provided to diagnose the hepatic diseases reproducibly and accurately by using a concentration ratio of an alpha1-acid glycoprotein to an asialo-alpha1-acid glycoprotein in blood. A kit for diagnosing the hepatic diseases is provided to perform the method conveniently and rapidly. A method for diagnosing hepatic diseases comprises the steps of: (a) measuring a concentration of an alpha1-acid glycoprotein in a serum sample; (b) measuring a concentration of an asialo-alpha1-acid glycoprotein in the serum sample; and (c) diagnosing the hepatic disease when a value calculated by dividing the concentration of the alpha1-acid glycoprotein in the serum sample into the concentration of the asialo-alpha1-acid glycoprotein in the serum sample is more than 10%. A kit for diagnosing the hepatic diseases comprises: (a) a first kit including a solid phase body where an antibody regarding an alpha1-acid glycoprotein is absorbed, a biotinylated alpha1-acid glycoprotein, a strepavidine solution coupled to an enzyme, a diluted solution of a serum sample, an enzyme substrate solution, a washing solution and an alpha1-acid glycoprotein standard solution; and a second kit including a solid phase body where an antibody regarding an asialo alpha1-acid glycoprotein is absorbed, an Armoracia rusticana peroxidase-RCA conjugate solution, an ortho-phenylenediamine(OPD) substrate solution, a serum diluted solution and an asialo-glycoprotein standard solution.

    Abstract translation: 本发明提供一种诊断肝脏疾病的方法,通过使用α1酸糖蛋白与血液中的脱唾液酸-α1-酸性糖蛋白的浓度比,可以高精度地准确地诊断肝脏疾病。 提供用于诊断肝脏疾病的工具箱,方便快捷地执行该方法。 一种诊断肝脏疾病的方法包括以下步骤:(a)测量血清样品中α1酸糖蛋白的浓度; (b)测量血清样品中脱唾液酸-α1酸性糖蛋白的浓度; 和(c)当通过将血清样品中的α-酸性糖蛋白的浓度除以血清样品中的脱唾液酸-α1-酸性糖蛋白的浓度而计算出的值大于10%时,诊断为肝脏疾病。 用于诊断肝脏疾病的试剂盒包括:(a)第一试剂盒,其包含其中吸收了关于α1-酸糖蛋白的抗体的固相体,生物素化的α1酸糖蛋白,与酶偶联的链脲霉酮溶液,稀释溶液 血清样品,酶底物溶液,洗涤溶液和α1酸糖蛋白标准溶液; 以及第二试剂盒,其包含固体相体,其中吸收了关于脱唾液酸α1-酸糖蛋白的抗体,防腐防腐剂过氧化物酶-RCA缀合物溶液,邻苯二胺(OPD)底物溶液,血清稀释溶液和脱唾液酸糖蛋白 标准解决方案

Patent Agency Ranking